Orlistat improved glycaemic
control, which resulted in the need to reduce the dose of glibenclamide (
glyburide) or
glipizide in almost half of the patients in one study. In other studies,
orlistat reduced the dose requirement for
metformin and insulin.
Monitor the outcome of concurrent use on blood sugar levels and adjust the antidiabetic treatment accordingly.